Steroids & Hormones FAQs

Corticosteroids are synthetic drugs modeled after hormones produced by the adrenal cortex. They are primarily used for their antiinflammatory and immunosuppressive effects across conditions such as asthma, autoimmune diseases, and dermatological disorders. 

Hormonal therapies involve replacing or regulating natural hormones, including insulin, thyroid hormones, pituitary hormones, and growth hormones, essential for treating endocrine and metabolic diseases. 

Corticosteroids emerged from early 20thcentury research into adrenal hormones. Synthetic versions were rapidly adopted for treating inflammation, autoimmune conditions, respiratory illnesses, allergies, and skin diseases due to their strong immunosuppressive effects.

Hormonal therapies grew out of advances in endocrinology, leading to treatments for diabetes, thyroid disorders, adrenal insufficiency, growth hormone deficiency, and reproductive hormone imbalance. Their development has closely followed increased understanding of glandular function and rising prevalence of endocrine disorders.

Corticosteroids are widely used for: 

• Respiratory diseases like asthma and COPD, where inhaled corticosteroids are firstline treatments.
• Autoimmune diseases such as rheumatoid arthritis and lupus.
• Skin and allergic conditions, treated with topical, oral, or injectable forms.
  Their broad availability across multiple dosage forms supports use in clinical and home settings. 

Hormonal therapies treat: 

• Diabetes, the primary global driver of endocrinology drug demand. 
• Thyroid diseases, via thyroid hormone replacement.  
• Growth hormone and pituitary disorders, using recombinant hormone therapies.
• Hormone replacement for adrenal and reproductive system disorders. 

The corticosteroids market is projected to grow from USD 5.89B in 2025 to USD 7.75B in 2030, driven by innovation in inhaled and targeted formulations and rising chronic disease prevalence. 

The endocrinology drugs market is far larger, expected to increase from USD 107.79B in 2025 to USD 144.86B in 2030, fueled by increases in diabetes and thyroid disorders. 

North America leads due to advanced healthcare infrastructure and high adoption of chronic disease therapies. The AsiaPacific region is the fastestgrowing market thanks to rising disease prevalence and expanding healthcare access.

Future corticosteroid development focuses on: 

• Selective glucocorticoid receptor modulators (SGRMs) that reduce side effects. 
• Digital inhalers and improved combination therapies for respiratory diseases. 
• Targeted and safer formulations, especially for autoimmune and dermatology applications. 

Key trends include: 

• Personalized medicine, with treatments tailored to genetics and metabolic profiles. 
• Targeted therapies for thyroid, adrenal, and pituitary disorders.  
• Wearable and devicebased treatments, including newly approved nonpharmacological endocrine therapies. 
• Digital monitoring, enabling continuous management of hormonal conditions. 

Despite being discovered several years ago, APIs such as hydrocortisone, betamethasone, and budesonide remain essential medicines today. Meeting modern demand for these molecules now depends on advanced manufacturing capabilities, particularly for highpotency and complex steroid chemistry. In parallel, novel steroid molecules with improved selectivity and safety profiles are expanding the future therapeutic landscape, increasing the need for advanced, flexible manufacturing capabilities.